International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 3 , Pages 649-655 , 1 November 2009

Urinary Symptom Flare in 712 125I Prostate Brachytherapy Patients: Long-Term Follow-Up

  • Mira Keyes, M.D.

      Affiliations

    • Provincial Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada
    • Corresponding Author InformationReprint requests to: Mira Keyes, M.D., F.R.C.P.C., Department of Surgery, University of British Columbia, Provincial Prostate Brachytherapy Program, British Columbia Cancer Agency, 600 W. 10th Ave., Vancouver, BC V5Z 4E6 Canada. Tel: (604) 877-6000; Fax: (604) 877-0505
    • ,
  • Stacy Miller, M.D.

      Affiliations

    • Provincial Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Veronika Moravan, M.Sc.

      Affiliations

    • Provincial Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Tom Pickles, M.D.

      Affiliations

    • Provincial Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Mitchell Liu, M.D.C.M.

      Affiliations

    • Provincial Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Ingrid Spadinger, Ph.D.

      Affiliations

    • Provincial Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • Vincent Lapointe, M.Sc.

      Affiliations

    • Provincial Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada
    • ,
  • W. James Morris, M.D.

      Affiliations

    • Provincial Prostate Brachytherapy Program, British Columbia Cancer Agency, Vancouver, BC, Canada

Received 14 October 2008 ,Revised 25 November 2008 ,Accepted 27 November 2008.

References 

  1. Grimm PD, Blasko JC, Sylvester JE, et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125) I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  2. Morris W, Keyes M, Palma D, et al. A population based study of biochemical and survival outcomes following permanent 125 iodine brachytherapy for low- and intermediate-risk prostate cancer. Urology. 2009;73:860–865
  3. Keyes M, Miller S, Moravan V, et al. McKenzie predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: Long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys. 2009;73:1023–1032
  4. Gelblum DY, Potters L, Ashley R, et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45:59–67
  5. Stone NN, Stock RG. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology. 2007;69:338–342
  6. Keyes M, Schellenberg D, Moravan V, et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys. 2006;64:825–834
  7. Cesaretti JA, Stone NN, Stock RG. Late exacerbation of urinary symptoms following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2002;54(2 Suppl. 1):45
  8. Morris WJ, Keyes M, Palma D, et al. Evaluation of dosimetric parameters and disease response in 1006 consecutive patients treated with 125-iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;73:1432–1438
  9. Spadinger I, Hilts M, Keyes M, et al. Prostate brachytherapy post-implant dosimetry: A comparison of suture-embedded and loose seed implants. Brachytherapy. 2006;5:165–173
  10. Blasko JC, Mate T, Sylvester JE, et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol. 2002;12:81–94
  11. O'Connor RC, Bales GT, Avila D, et al. Variability of the International Prostate Symptom Score in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2003;37:35–37
  12. Lawton CA, Won M, Pilepich MV, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys. 1991;21:935–939
  13. Macdonald AG, Keyes M, Kruk A, et al. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?. Int J Radiat Oncol Biol Phys. 2005;63:155–163
  14. Lehrer S, Cesaretti J, Stone NN, et al. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. BJU Int. 2006;98:979–981
  15. Crook J, Fleshner N, Roberts C, et al. Long-term urinary sequelae following 125iodine prostate brachytherapy. J Urol. 2008;179:141–146
  16. Niehaus A, Merrick GS, Butler WM, et al. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64:136–143
  17. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637–649
  18. Andreassen CN, Overgaard J, Alsner J, et al. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after post-mastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2006;64:776–783
  19. Cesaretti JA, Stock RG, Lehrer S, et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys. 2005;61:196–202
  20. Olive PL, Banath JP, Keyes M. Residual gammaH2AX after irradiation of human lymphocytes and monocytes in vitro and its relation to late effects after prostate brachytherapy. Radiother Oncol. 2008;86:336–346
  21. Keyes M, Pugh T, Moore R, et al. Variants in DNA repair genes and their association with late side-effects in prostate brachytherapy patients. Brachytherapy. 2008;7:122–123

 Presented at Canadian Association of Radiation Oncology, September 2007, Calgary, Alberta, Canada and the American Brachytherapy Society Meeting, May 2007, Chicago, IL.

 Conflict of interest: none.

PII: S0360-3016(08)03848-0

doi: 10.1016/j.ijrobp.2008.11.043

International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 3 , Pages 649-655 , 1 November 2009

Article Tools

* Image Usage & Resolution